CD274 and non-small cell lung carcinoma: Immunotherapy in perioperative setting demonstrated robust efficacy, with significant pathological response and EFS benefits across all PD-L1 subgroups.<h4>Conclusion</h4>This meta-analysis supports immunotherapy within perioperative care for resectable NSCLC, emphasizing PD-L1 expression as a predictive biomarker.